University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Urology of Indiana, Indianapolis, Indiana.
J Urol. 2020 Oct;204(4):748-753. doi: 10.1097/JU.0000000000001074. Epub 2020 Apr 7.
We examined rates of Grade Group 4 downgrading at radical prostatectomy among men diagnosed with high and very high risk prostate cancer at biopsy.
A pooled cohort of 1,776 patients from 3 tertiary referral centers who underwent radical prostatectomy for National Comprehensive Cancer Network® high risk (prostate specific antigen greater than 20 ng/ml, or Grade Group 4-5, or clinical stage T3 or greater) or very high risk (primary Gleason pattern 5, or more than 4 biopsy cores with Grade Group 4-5, or 2 or more high risk features) disease from 2005 to 2015 were reviewed. Overall 893 patients with Grade Group 4 disease at biopsy were identified and 726 patients were available for analysis. Multivariable logistic regression models were fit to determine factors associated with downgrading to Grade Group 3 or less at radical prostatectomy.
Overall 333 (45%) cases were downgraded to Grade Group 3 or less at radical prostatectomy. Of these cases 198 (27%) had concordant Grade Group 4 biopsy and radical prostatectomy pathology and 195 (27%) were upgraded at radical prostatectomy to Grade Group 5. Of high risk cases with biopsy Grade Group 4 disease 49% had any downgrading vs 29% of very high risk cases (p <0.0001). Downgrading to Grade Group 2 or less occurred in 16% (98 of 604) of high risk and 7% (8 of 122) of very high risk cases (p <0.01). Downgraded cases had a lower prostate specific antigen, fewer positive biopsy cores and lower clinical stage (p <0.01). On multivariable analysis fewer positive biopsy cores were significantly associated with downgrading at radical prostatectomy (p <0.01).
In this cohort of patients with high risk/very high risk prostate cancer, downgrading from biopsy Grade Group 4 at radical prostatectomy occurred less frequently than in other published reports. Any downgrading was significantly less common in very high risk compared to high risk patients, and downgrading to Grade Group 2 or less occurred in a minority of cases in high risk and very high risk patients.
我们研究了在接受根治性前列腺切除术的高风险和极高风险前列腺癌患者中,活检诊断为 4 级分组的降级率。
本研究纳入了来自 3 个三级转诊中心的 1776 例患者,这些患者于 2005 年至 2015 年期间因国家综合癌症网络高风险(前列腺特异抗原大于 20ng/ml,或 4-5 级分组,或临床分期 T3 或更大)或极高风险(原发性 Gleason 模式 5,或 4 个以上活检核有 4-5 级分组,或 2 个或更多高危特征)疾病而接受根治性前列腺切除术。总体上,有 893 例患者在活检时患有 4 级分组疾病,其中 726 例患者可用于分析。采用多变量逻辑回归模型确定与根治性前列腺切除术后降级至 3 级或更低分组相关的因素。
总体上,有 333 例(45%)患者在根治性前列腺切除术后降级至 3 级或更低分组。其中 198 例(27%)患者在活检和根治性前列腺切除术后病理检查中存在一致的 4 级分组,195 例(27%)患者在根治性前列腺切除术后升级为 5 级分组。在高风险病例中,有 49%的患者出现任何降级,而在极高风险病例中,有 29%的患者出现降级(p<0.0001)。在高风险病例中,有 16%(98/604)降级至 2 级或更低分组,而在极高风险病例中,有 7%(8/122)降级至 2 级或更低分组(p<0.01)。降级病例的前列腺特异抗原较低,阳性活检核数较少,临床分期较低(p<0.01)。多变量分析显示,阳性活检核数较少与根治性前列腺切除术后降级显著相关(p<0.01)。
在本研究队列中,高风险/极高风险前列腺癌患者的根治性前列腺切除术后降级率低于其他已发表的报道。与高风险患者相比,任何降级在极高风险患者中均明显较少见,而在高风险和极高风险患者中,降级至 2 级或更低分组的病例较少。